Dual Therapy Holds Its Own in Treatment-Naive HIV
MONTREAL — A two-drug combination using a generic formulation of the protease inhibitor darunavir/ritonavir plus lamivudine appeared to control HIV as well as the same combination with added tenofovir, according to results of the phase IV ANDES trial reported here. In the intention-to-treat analysis, 91% patients on the dual therapy achieved undetectable viral loads using […]